Germline Variation in HSD3B1 as a Novel Biomarker in Prostate Cancer
Abstract
In lay terms we assessed whether there is a clinical impact of inheriting a variant form (allele) of the HSD3B1 gene, previously shown to enable prostate cancer cells to make their own derivative of testosterone that can drive tumor progression, despite castration. We have demonstrated in three independent groups of men treated with androgen deprivation therapy (ADT) that the number of inherited copies of the variant allele corresponds to clinical outcomes (i.e. likelihood of disease progression, risk of spread to the bones and other distant sites, and death). Men possessing the variant HSD3B1allele have worse clinical outcomes than men who have not inherited that allele.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2016
- Accession Number
- AD1029669
Entities
People
- Jason Hearn
- Nima Sharifi
Organizations
- Board of Regents of the University of Michigan